Eloxx Pharmaceuticals, Inc.

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Antisense, Oligonucleotides
  • Pharmaceuticals

Other Names/Subsidiaries

  • Eloxx Limited
  • Eloxx Pharmaceuticals, Ltd.
  • Fabrus, Inc.
  • Senesco Technologies, Inc.
  • Sevion Therapeutics, Inc.
  • Zikani Therapeutics Inc.
See more in Biomedtracker

Latest on Eloxx Pharmaceuticals, Inc.

Scrip

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

These are interesting times for Almirall and CEO Carlos Gallardo believes the Spanish firm holds “a unique position as the only company that focuses exclusively on medical dermatology and has capabili

Scrip

Almirall Upbeat Over Initial Sales Of Atopic Dermatitis Drug

 
• By Kevin Grogan

Almirall SA has unveiled the first sales for its closely-watched atopic dermatitis drug Ebglyss and the Spanish firm is pleased with the initial launch data on a drug which will be key to the firm's

Scrip

Almirall Casts Its Net To Cover Butterfly Skin Disease

 
• By Kevin Grogan

Who: Almirall SA and Eloxx Pharmaceuticals, Inc. What: A global licensing agreement which will see the Spanish firm develop and commercialize ZKN-013 in orphan dermatological diseases Why: Alm

Scrip

Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers

 
• By Joseph Haas, John Davis, and Anju Ghangurde

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Collaborates With Artios On DD